策略报告 | 投资策略 行业比较周报 证券研究报告 中美会谈下，自主可控板块的节奏与机会 核心结论：6 月 5 日，习近平主席同美国总统特朗普通电话，指出美方应实 事求是看待取得的进展，撤销对中国实施的消极举措；并欢迎特朗普再次访 华。双方经贸协商未完待续，自主可控仍是长期逻辑。自主可控的第一个逻 辑是国家政策多年布局下的积累；自主可控的第二个逻辑是国产替代。穿透 到二级行业，短期可以关注估值处于低位的方向，中期关注产业节奏。估值 方面，前期估值处于低位的板块主要为军工、医药、电子；产业节奏方面， 军工→信创→医药→先进制造。 中美关税会谈破冰后，双方经贸协商未完待续，自主可控仍是长期逻辑。5 月 12 日，中美双方发布《中美日内瓦经贸会谈联合声明》，中美双方关税 中枢回落，后续或仍有多轮协商。一方面，参考 2018 年-2020 年中美经贸谈 判，总共经历了十三轮高级别磋商，历时近两年才签署第一阶段经贸协议。 6 月 5 日，习近平主席同美国总统特朗普通电话，指出美方应实事求是看待 取得的进展，撤销对中国实施的消极举措；并欢迎特朗普再次访华。 另一方面，4 月中旬美方发起的 232 调查和 301 调查仍在 ...

策略报告 | 投资策略 自主可控的第一个逻辑是国家政策多年布局下的积累，顶层设计重视，现代 化产业体系建设要求固链、补链、延链，顶层设计对自主可控领域重视程度 高；自主可控的第二个逻辑是国产替代，即中国对美反制措施可能推升中国 对美进口商品价格，导致对美依赖度较高的商品种类出现供给缺口，国内供 给端替代供给缺口下相关板块有望看到盈利驱动下的业绩改善。 穿透到二级行业，短期可以关注估值处于低位的方向，中期关注产业节奏。 估值方面，前期估值处于低位的板块主要为军工、医药、电子。 产业趋势投资涵盖三个阶段，当前自主可控多数子板块位于阶段一的尾声。 如何能够迈向阶段二开启双击行情？先看产能周期后看业绩，即标的是否开 启大额资本开支以形成产业链的完善可以作为是否进入阶段二的判断，业绩 大面积改善可以作为阶段二拐点出现的确认。 从这个角度，我们判断自主可控各板块产业节奏：军工→信创→医药→先进 制造。 行业比较周报 证券研究报告 中美会谈下，自主可控板块的节奏与机会 核心结论：6 月 5 日，习近平主席同美国总统特朗普通电话，指出美方应实 事求是看待取得的进展，撤销对中国实施的消极举措；并欢迎特朗普再次访 华。双方经贸协 ...

Investment Rating - The report gives a "Buy" rating for the company with a target price of 45.2 CNY, compared to the current price of 36.35 CNY [6]. Core Insights - The company, TaiLing Microelectronics, is a leader in wireless IoT SoC, focusing on cutting-edge technology and binding with industry-leading clients. It has a strong market position in multiple protocol technologies, including low-power Bluetooth and Zigbee [1][3]. - The company has shown significant growth in recent financial performance, with a projected revenue of 844 million CNY in 2024, representing a year-over-year increase of 32.69%, and a net profit of 97.41 million CNY, up 95.71% year-over-year [2][24]. - The company is actively investing in R&D, with R&D expenses reaching 220 million CNY in 2024, accounting for 26.06% of revenue, and a total of 531 million CNY invested over the past three years [2][41]. Summary by Sections Company Overview - TaiLing Microelectronics, established in June 2010, specializes in the R&D, design, and sales of wireless IoT system-level chips, becoming a representative enterprise in the field with a comprehensive product range [1][13]. Financial Analysis - The company's revenue is primarily driven by IoT chips, which are expected to generate 765 million CNY in 2024, a 31.53% increase year-over-year. Audio chips are also experiencing rapid growth, with projected revenue of 76 million CNY, up 61.98% year-over-year [24][26]. - The company has achieved a gross margin of 48.34% in 2025, with IoT chip margins at 47.17% and audio chip margins significantly higher at 58.36% [28][41]. R&D Analysis - The company emphasizes R&D as a driver of growth, with a focus on developing new technologies and products, including the launch of AI chips and advancements in low-power wireless communication standards [35][38]. - In 2024, the company introduced the TL721X series AI chips and the TLEdgeAI-DK development platform, marking its entry into the AIoT era [4][36]. Industry Analysis - The global SoC market is projected to reach approximately 186.48 billion USD by 2025, with a compound annual growth rate of 8.01% from 2025 to 2030 [43][44]. - The low-power Bluetooth chip market is expected to grow from 3.36 billion USD in 2023 to 8.59 billion USD by 2032, indicating a robust demand for wireless communication technologies [48][52].

Investment Rating - The report assigns an "Accumulate" rating for the company, marking it as the first coverage with a target price of HKD 29.50, compared to the current price of HKD 27.2 [5]. Core Viewpoints - The company is recognized as a leading innovation-driven pharmaceutical enterprise, focusing on oncology, anti-infection, central nervous system, metabolic diseases, and autoimmune diseases. It is projected to achieve a revenue of HKD 12.26 billion in 2024, representing a 21% year-on-year growth, and a net profit of HKD 4.372 billion, reflecting a 33% increase [1][5]. - The company has successfully launched multiple innovative drugs, with a strong pipeline that is expected to drive future growth. The sales of innovative drugs are anticipated to continue increasing, with a projected revenue of HKD 9.477 billion in 2024, marking a 38.1% year-on-year growth [16][24]. Summary by Sections 1. Innovation and R&D - The company has established a comprehensive R&D system, employing over 1,800 professionals and creating several national-level research institutions. It has been recognized as a key high-tech enterprise and a national technology innovation demonstration enterprise [14][26]. - The company has eight innovative drugs approved for market, including Amelotin (甲磺酸阿美替尼片) and Fluoromethylnitro (甲磺酸氟马替尼片), which are expected to contribute significantly to revenue growth [16][17]. 2. Market Performance - The sales of Amelotin, the first domestic third-generation EGFR TKI, are projected to grow rapidly, with a compound annual growth rate (CAGR) of 214% from 2020 to 2024, capturing approximately 28% of the total sales of third-generation EGFR TKIs by 2024 [2]. - The company has also seen significant sales growth in Fluoromethylnitro, with a 54% increase in 2023 and a projected 36% growth in 2024 [3]. 3. Future Growth Potential - The company has a robust pipeline with several innovative drugs in various stages of clinical trials, including HS-20089 and HS-20093, which have entered phase II and III trials, respectively [4]. - The company is expanding its market presence through collaborations, such as granting global exclusive licensing rights for HS-10535 to Merck, indicating strong potential for future revenue streams [4][5]. 4. Financial Projections - Revenue forecasts for 2025, 2026, and 2027 are projected at HKD 13.741 billion, HKD 15.567 billion, and HKD 17.374 billion, respectively, with net profits expected to reach HKD 4.746 billion, HKD 5.336 billion, and HKD 5.850 billion [5].

Investment Rating - The report assigns a "Buy" rating for the company with a target price of 45.2 CNY, compared to the current price of 36.35 CNY [6]. Core Insights - The company, TaiLing Microelectronics, is a leader in wireless IoT SoC, focusing on cutting-edge technology and binding with industry-leading clients. It has a strong market position in multiple protocol technologies, including low-power Bluetooth and Zigbee [1][3]. - The company has shown significant growth in recent financial performance, with a projected revenue of 844 million CNY in 2024, representing a year-on-year increase of 32.69%, and a net profit of 97.41 million CNY, up 95.71% year-on-year [2][24]. - The company is heavily investing in R&D, with R&D expenses reaching 220 million CNY in 2024, accounting for 26.06% of revenue, and a total of 531 million CNY invested over the past three years [2][41]. Summary by Sections Company Overview - TaiLing Microelectronics, established in June 2010, specializes in the R&D, design, and sales of wireless IoT system-level chips, becoming a representative enterprise in the field with a comprehensive product range [1][13]. Financial Analysis - The company's revenue is primarily driven by IoT chips, which are expected to generate 765 million CNY in 2024, a 31.53% increase year-on-year. Audio chips are also experiencing rapid growth, with projected revenue of 76 million CNY, up 61.98% year-on-year [24][26]. - The company has achieved a gross margin of 48.34% in 2025, with IoT chip margins at 47.17% and audio chip margins significantly higher at 58.36% [28][41]. R&D Analysis - The company emphasizes R&D-driven growth, with a focus on developing new technologies and products, including the launch of AI chips and advancements in low-power wireless communication standards [35][36]. - In 2024, the company introduced the TL721X series AI chips and the TLEdgeAI-DK development platform, marking its entry into the AIoT era [4][36]. Industry Analysis - The global SoC market is projected to reach approximately 186.48 billion USD by 2025, with a compound annual growth rate of 8.01% from 2025 to 2030 [43]. - The low-power Bluetooth chip market is expected to grow from 3.36 billion USD in 2023 to 8.59 billion USD by 2032, indicating a robust demand for wireless communication technologies [48][52].

Investment Rating - The report assigns an "Accumulate" rating for the company, marking it as the first coverage with a target price of HKD 29.50, compared to the current price of HKD 27.2 [5]. Core Viewpoints - The company is recognized as a leading innovative pharmaceutical enterprise with a focus on oncology, anti-infection, central nervous system, metabolic diseases, and autoimmune diseases. It has shown robust performance with a projected revenue of HKD 12.26 billion for 2024, representing a 21% year-on-year growth, and a net profit of HKD 4.372 billion, reflecting a 33% increase [1][5]. - The company has successfully launched multiple innovative drugs, with significant sales growth in its key products, particularly in the oncology sector, which is expected to account for 66.24% of total revenue by 2024 [17][24]. Summary by Sections 1. Innovation and R&D - The company has established a comprehensive R&D system with over 1,800 professional researchers, focusing on drug discovery and clinical research. It has been recognized as a national high-tech enterprise and a national technology innovation demonstration enterprise [14][26]. - The company has eight innovative drugs approved for market, including Amelotin (甲磺酸阿美替尼片) and Fluoromethine (甲磺酸氟马替尼片), which have shown strong sales performance [16][17]. 2. Sales Performance - The sales of Amelotin are projected to grow at a compound annual growth rate (CAGR) of 214% from 2020 to 2024, capturing approximately 28% of the total sales for third-generation EGFR TKIs by 2024 [2]. - The sales of Fluoromethine increased by 54% in 2023 compared to the previous year, with a projected growth of 36% in 2024 [3]. 3. Future Growth Potential - The company has a robust pipeline with several innovative drugs in various stages of clinical trials, including HS-20089 and HS-20093, which have entered phase II and III trials, respectively [4]. - The company is expanding its market presence with global licensing agreements for its innovative drugs, indicating strong potential for future revenue growth [4][5]. 4. Financial Forecast - The revenue forecast for the company is set at HKD 13.741 billion, HKD 15.567 billion, and HKD 17.374 billion for the years 2025, 2026, and 2027, respectively, with net profits projected at HKD 4.746 billion, HKD 5.336 billion, and HKD 5.850 billion [5].

Group 1 - The report indicates that in May, the equity market experienced a mixed performance with financial and pharmaceutical sectors leading the gains, while the technology sector saw a slight decline, with the Sci-Tech 50 Index dropping by 3.5% [11][13] - The convertible bond market showed resilience, with the overall market rising by 2.22% and financial convertible bonds increasing by 2.94%, outperforming other sectors [2][13] - The report highlights that the valuation of convertible bonds has retreated from high levels, with the premium rate for bonds trading at par falling below 22%, which is around the 50th percentile of 2017 [2][29] Group 2 - The economic outlook for June suggests a low visibility macroeconomic environment, with A-share indices at historically high valuation percentiles, indicating potential for a volatile market with limited upward elasticity [3][50] - The report emphasizes the importance of focusing on specific sectors such as technology, food security, and high-dividend defensive sectors, as well as industry leaders with low exposure to U.S. exports and strong domestic demand [3][50] - The convertible bond market is expected to face challenges in upward valuation due to credit risk adjustments, suggesting a cautious approach to bond positioning while waiting for clearer market signals [4][44] Group 3 - The report notes that in May, the agricultural and electronic semiconductor-themed convertible bonds led the market, while the top ten declining bonds were primarily those with strong redemption or those that peaked and then fell [40][41] - The analysis of the convertible bond market indicates that the credit risk pricing feedback is relatively controllable, and it suggests a balanced allocation between low-priced debt-oriented bonds and growth-oriented equity bonds [4][44] - The report provides a specific convertible bond portfolio for June, including bonds from sectors such as new energy, cyclical industries, and electronics, highlighting their potential for performance [4][52]

Investment Rating - The investment rating for the company is "Buy" with a 6-month outlook maintained [8] Core Views - The company is positioned as a pioneer in new materials, with strong growth potential in key areas such as low dielectric/low expansion electronic fabrics and high-pressure hydrogen storage bottles, indicating a significant opportunity for valuation reappraisal [1][2] - The projected revenue and net profit from the specialty fiberglass fabric segment for 2025-2027 are estimated to be 8.5 billion, 16.6 billion, and 24.5 billion CNY, with corresponding net profits of 1.8 billion, 4.9 billion, and 8.2 billion CNY, reflecting substantial year-on-year growth [1][37] - The hydrogen bottle segment is expected to generate revenues of 3.6 billion, 6.9 billion, and 13.2 billion CNY from 2025 to 2027, with net profits of 0.3 billion, 0.7 billion, and 1.5 billion CNY, also showing strong growth rates [1][6] Summary by Sections New Materials - The company is in the early stages of industrializing new materials, achieving technological breakthroughs in low dielectric/low expansion electronic fabrics and high-pressure hydrogen storage bottles [1] - The low dielectric electronic fabric (LowDK) is designed to reduce energy loss during signal transmission, with production capacity expected to increase significantly by 2026-2027 [4][22] - The low expansion electronic fabric (LowCTE) is primarily used in high-end mobile phone chip packaging, with a focus on maintaining low thermal expansion coefficients [5][31] Financial Data and Valuation - The estimated market value for the new materials segment in 2026 is around 150 billion CNY, while the main business is projected to be valued at approximately 240 billion CNY, leading to a total reasonable market value of about 390 billion CNY for the company [2] - The company's revenue for 2023 is reported at 25.89 billion CNY, with a projected growth rate of 20.54% for 2025 [7] Hydrogen Bottles - The company operates five manufacturing bases for hydrogen bottles, with a production capacity of 100,000 III-type hydrogen bottles and 30,000 IV-type hydrogen bottles annually [6][40] - The company has achieved the highest market share in the domestic hydrogen bottle market, with significant applications in hydrogen-powered vehicles [6][41]

Investment Rating - The investment rating for the company is "Buy" with a 6-month outlook maintained [8] Core Views - The company is positioned as a pioneer in new materials, with strong development potential in key areas such as low dielectric/low expansion electronic fabrics and high-pressure hydrogen storage bottles, indicating a potential valuation reconfiguration [1][2] - Revenue projections for the special glass fiber fabric segment are estimated at 850 million, 1.66 billion, and 2.45 billion yuan for 2025-2027, with corresponding net profits of 180 million, 490 million, and 820 million yuan, reflecting significant year-on-year growth [1][37] - The hydrogen bottle segment is expected to generate revenues of 360 million, 690 million, and 1.32 billion yuan for 2025-2027, with net profits of 30 million, 70 million, and 150 million yuan, also showing strong growth [1][6] Summary by Sections New Materials Sector - The company is focusing on high-performance special glass fiber fabrics, particularly low dielectric electronic fabrics (LowDK) and low expansion (LowCTE) electronic fabrics, which are crucial for communication infrastructure and semiconductor packaging [3][20] - The company has established five production lines for low dielectric glass fiber, with a total capacity of approximately 6,150 tons, and plans to increase production capacity further [4][22] Low Dielectric Electronic Fabrics - The first generation of low dielectric electronic fabrics is expected to have production volumes of 1.5 million, 3 million, and 4 million meters per month from 2025 to 2027, with prices projected to decrease slightly [4][36] - The second generation is anticipated to have production volumes of 150,000, 300,000, and 600,000 meters per month, with increasing unit prices and net profit margins [4][36] Low Expansion Electronic Fabrics - The low expansion electronic fabrics are primarily used in high-end mobile phone chip packaging, with production volumes expected to rise significantly over the next few years [5][31] Hydrogen Bottles - The company operates five manufacturing bases for hydrogen bottles, with a production capacity of 100,000 III-type hydrogen bottles and 30,000 IV-type hydrogen bottles annually [6][40] - The company has achieved the highest market share in the domestic hydrogen bottle market and is expanding its product offerings to include various hydrogen storage solutions [6][41]

Group 1 - The report highlights the optimistic growth in the global power equipment market, projected to exceed $700 billion by 2025, with significant investments in the power grid expected to surpass $450 billion [3][23] - The company is positioned as a leader in the high-end diesel generator market, benefiting from strategic partnerships and a robust supply chain, which enhances its pricing power [3][24] - Revenue forecasts for the company indicate substantial growth, with expected revenues of 2.76 billion, 3.76 billion, and 4.75 billion yuan for 2025, 2026, and 2027 respectively, reflecting year-on-year increases of 689%, 36%, and 26% [3][24] Group 2 - The offshore wind power sector is anticipated to experience a new wave of growth, with domestic installations expected to reach 12 GW in 2025, a 200% increase year-on-year [4][6] - The company is expanding its production capacity and focusing on the deep-sea wind market, with significant investments in export terminals to meet growing international demand [4][6] - Profit forecasts for the company suggest net profits of 8.6 billion, 11.0 billion, and 13.1 billion yuan for 2025, 2026, and 2027, with corresponding price-to-earnings ratios of 15.8, 12.3, and 10.3 [4][6] Group 3 - The nuclear power sector is witnessing accelerated investment, with completed investments reaching 36.26 billion yuan in the first four months of 2025, a 36.64% year-on-year increase [12][27] - The company is well-positioned to capitalize on the modular construction market for nuclear power, with a projected market size of approximately 864 billion yuan from 2025 to 2030 [12][28] - Expected net profits for the company are projected to be 2.3 billion, 2.5 billion, and 2.9 billion yuan for 2025, 2026, and 2027, with price-to-earnings ratios of 20, 19, and 16 [12][30] Group 4 - The magnesium alloy market is experiencing rapid growth, with the company focusing on expanding its production capacity to meet increasing demand in various sectors, including aerospace and automotive [7][31] - Revenue for the company is expected to reach 4.09 billion yuan in 2024, reflecting a 16.01% year-on-year increase, with continued growth anticipated in subsequent years [7][31] - The company is actively integrating into the lightweight strategy of leading automotive manufacturers, enhancing its market position [7][31]